



IFW

Patent Application
Attorney Docket No. PC27829A



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 03 day of February 2005.

By 
(Signature of person mailing)
Erica L. Smith
(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PRE APPLICATION OF: Jerry R. Colca :
APPLICATION NO.: 10/728,399 : Examiner: To be Assigned
FILING DATE: December 5, 2003 : Group Art Unit: 1636
TITLE: Antisense Modulation of mitoNEET Expression :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date: 2/28/2005
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0041

Respectfully submitted,

Gabriel L. Kleiman
Attorney for Applicant(s)
Reg. No. 40,861

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) MAR 03 2005	ATTY. DOCKET NO. PC27829A	SERIAL NO. 10/728,399
	APPLICANT Jerry R. Colca	
	FILING DATE December 5, 2003	GROUP 1636

U.S. PATENT DOCUMENTS


[illegible]

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	2	4	3	7	1	6	11/29/01	International	A61K	31/00		
	WO	9	4	2	5	0	2	6	4/25/94	International	A61K	31/42		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Chang, et al., <u>Diabetes</u> , "Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? Mice" , Vol. 32, pages 839-845 (1983)
			Colca and Morton <u>New Antidiabetic Drugs</u> , "Antihyperglycaemic Thiazolidinediones: Ciglitazone and Its Analogues", C.J. Bailey and P.R. Flatt, eds., Smith-Gordon, New York, pages 255-261 (1990)
			Dreyer, C., et al., <u>Cell</u> , "Control of the peroxisomal β -oxidation pathway by a novel family of nuclear hormone receptors", Vol. 68, pages 879-887 (1992)
			Goke, R., et al., <u>Digestion</u> , "Pioglitazone Inhibits Growth of Carcinoid Cells and Promotes TRAIL-Induced Apoptosis by Induction of p21", Vol. 64(2), pages 75-80 (2001)
			Gottlicher, <u>Proc. Natl. Acad.</u> , "Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor", Vol. 89, pages 4653-4657 (1992)
			Harris and Kletzien, <u>Molecular Pharmacology</u> , "Localization of a pioglitazone response element in the adipocyte fatty



00INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC27829A	SERIAL NO. 10/728,399
			APPLICANT Jerry R. Colca	
			FILING DATE December 5, 2003	GROUP 1636
			acid-binding protein gene", Vol. 45, pages 439-445 (1994)	
			Hiragum, et al., <u>Journal Cell Physiology</u> , "Preadipocyte Differentiation in Vitro: Identification of a Highly Active Adipogenic Agent:", Vol. 134, pages 124-130 (1988)	
			Isseman and Green, <u>Nature</u> , "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators" Vol. 347, pages 645-650 (1990)	
			Itami, A., et al., <u>International Journal of Cancer</u> , "Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both <i>in vitro</i> and <i>in vivo</i> ", Vol. 94(3), pages 370-376 (2001)	
			Keller and Whali, <u>Trends Endocrinolgy Met.</u> , Vol. 4, pages 291-296 (1993)	
			Kletzien, et al., <u>Mol. Pharmacology</u> , "Enhancement of adipocyte differentiation by an insulin-sensitizing agent", Vol. 41, pages 393-398 (1992)	
			Kliwer, et al., <u>Proc. Natl. Acad. Sci.</u> , "Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors", Vol. 91, pages 7355-7359 (1994)	
			Mueller, E., et al., <u>Molecular Cell</u> , "Terminal Differentiation of Human Breast Cancer through PPAR γ ", Vol. 1(3), pages 465-470 (1998)	
			Nolan, et al., <u>New England Journal of Medicine</u> , "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone", Vol. 331, pages 1188-1193 (1994)	
			Okano, H., et al., <u>Anti-Cancer Drugs</u> , "Peroxisome proliferator-activated receptor [<i>gamma</i>] augments tumor necrosis factor family-induced apoptosis in hepatocellular carcinoma", Vol. 13(1), pages 59-65 (2002)	
			Sparks, et al., <u>Journal Cell Physiology</u> , "Antidiabetic AD4743 Enhances Adipocyte Differentiation of 3T3 Mesenchymal Stem Cells", Vol. 146, pages 101-109 (1991)	
			Tankaka, T., et al., <u>Cancer Research</u> , "Ligands for Peroxisome Proliferator-activated Receptors α and γ Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats" Vol. 61(6), pages 2424-2428 (2001)	
			Tontonoz, et al., <u>Genes and Development</u> , "mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer" Vol. 8, pages 1224-1234 (1994)	
			Williams, et al., <u>Diabetes</u> , Vol. 42, page 59A (1993)	
			Zhu, et al., "Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver" <u>J. Biol. Chem.</u> , Vol. 268, pages 26817-26820 (1993)	
			Genbank: NM 018464	
			Genbank: NM 134007	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.